Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment

Puma Biotechnology (NASDAQ: PBYI ) is the ever-tenacious odd duck with an approved drug, reasonably good sales, and a continuing pipeline, but no market appreciation. There are very good reasons for this, but I have remained cautiously optimistic aboutI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence ...